My message to the leaders assembling here in Munich is clear: global health security will never be a zero-sum game.

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Climate-driven extreme weather disasters and resource conflicts can intensify social and political rifts both domestically ...

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...